Website: twistbioscience.com | LinkedIn: linkedin.com/company/twist-bioscience
Writing DNA at Scale
How Twist Bioscience turned silicon-based DNA synthesis into the engine behind modern genomics, drug discovery, and AI-driven biology
At a glance
- Company: Twist Bioscience (twistbioscience.com), NASDAQ: TWST
- Headquarters: South San Francisco, California
- Focus: Synthetic DNA and DNA-based products: genes, oligo pools, NGS target enrichment, and protein and antibody discovery solutions
- Fiscal 2026: record revenue of $459.4 million, up 22% year over year
- Working with PSG on: Fractional business development
A new way to make DNA
For decades, synthetic DNA was made one tube at a time. Twist changed the math. Its proprietary platform writes DNA on silicon, miniaturizing the chemistry so thousands of sequences can be made in parallel, with high quality and at a scale traditional methods can’t match.
That single breakthrough has grown into a broad portfolio serving researchers in academia, diagnostics, and biopharma around the world.
What Twist delivers
- DNA synthesis: genes, gene fragments, clonal genes, and oligo pools for synthetic biology, cloning, and library construction
- NGS applications: target enrichment panels and workflows that power genomic research and clinical diagnostics
- Protein and antibody solutions: discovery, optimization, and characterization services for biopharma
- Fuel for AI-enabled discovery: high-throughput DNA that lets AI-driven drug discovery teams design, build, and test at scale
Momentum you can measure
Twist just closed a record fiscal 2026. Revenue reached $459.4 million, up 22%, with Q4 marking its 15th consecutive quarter of sequential growth and gross margin improving to 52.4%. Growth has been led by DNA Synthesis and Protein Solutions, where customers pursuing AI-enabled discovery are scaling up, and by strong uptake from pharma and biotech therapeutics teams.